Relay Therapeutics, Inc. $RLAY Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC lessened its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) by 79.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 34,035 shares of the company’s stock after selling 127,792 shares during the period. Voya Investment Management LLC’s holdings in Relay Therapeutics were worth $89,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in RLAY. Murchinson Ltd. acquired a new stake in shares of Relay Therapeutics during the 1st quarter worth about $26,000. DRW Securities LLC acquired a new stake in shares of Relay Therapeutics during the 1st quarter worth about $28,000. AssuredPartners Investment Advisors LLC acquired a new stake in shares of Relay Therapeutics during the 1st quarter worth about $29,000. Wealth Enhancement Advisory Services LLC purchased a new position in Relay Therapeutics during the 1st quarter worth approximately $41,000. Finally, CWM LLC increased its position in Relay Therapeutics by 368.6% during the first quarter. CWM LLC now owns 20,269 shares of the company’s stock worth $53,000 after buying an additional 15,944 shares during the period. Institutional investors and hedge funds own 96.98% of the company’s stock.

Insider Activity at Relay Therapeutics

In other Relay Therapeutics news, CFO Thomas Catinazzo sold 18,380 shares of the stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $3.68, for a total transaction of $67,638.40. Following the transaction, the chief financial officer owned 335,295 shares of the company’s stock, valued at $1,233,885.60. This trade represents a 5.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Donald A. Bergstrom sold 26,701 shares of the stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $3.68, for a total value of $98,259.68. Following the transaction, the insider directly owned 552,720 shares in the company, valued at approximately $2,034,009.60. This represents a 4.61% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 149,226 shares of company stock valued at $542,926 over the last three months. Insiders own 4.87% of the company’s stock.

Relay Therapeutics Stock Performance

RLAY opened at $5.32 on Thursday. The business’s fifty day moving average is $3.90 and its two-hundred day moving average is $3.36. The company has a market cap of $917.22 million, a price-to-earnings ratio of -2.73 and a beta of 1.74. Relay Therapeutics, Inc. has a one year low of $1.77 and a one year high of $7.07.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.08. The company had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.07 million. On average, analysts predict that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on RLAY. Raymond James Financial decreased their price objective on Relay Therapeutics from $29.00 to $19.00 and set a “strong-buy” rating for the company in a report on Friday, August 8th. Guggenheim began coverage on shares of Relay Therapeutics in a research report on Thursday, September 4th. They issued a “buy” rating and a $15.00 price target for the company. Finally, HC Wainwright reduced their price target on shares of Relay Therapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, August 26th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $16.50.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.